This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hung, C.-F.
Right arrow Articles by Wu, T.-C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hung, C.-F.
Right arrow Articles by Wu, T.-C.

 Previous Article  |  Next Article 

Journal of Virology, March 2002, p. 2676-2682, Vol. 76, No. 6
0022-538X/02/$04.00+0     DOI: 10.1128/JVI.76.6.2676-2682.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Improving DNA Vaccine Potency by Linking Marek's Disease Virus Type 1 VP22 to an Antigen

Chien-Fu Hung,1 Liangmei He,1 Jeremy Juang,1 Tzyy-Jye Lin,1 Morris Ling,1 and T.-C. Wu1,2,3,4*

Pathology,1 Oncology,2 Obstetrics and Gynecology,3 Molecular Microbiology and Immunology, The Johns Hopkins Medical Institutions, Baltimore, Maryland 212054

Received 17 September 2001/ Accepted 13 December 2001

We have previously employed an intercellular spreading strategy using herpes simplex virus type 1 (HSV-1) VP22 protein to enhance DNA vaccine potency because DNA vaccines lack the intrinsic ability to amplify in cells. Recently, studies have demonstrated that the protein encoded by UL49 of Marek's disease virus type 1 (MDV-1) exhibits some degree of homology to the HSV-1 VP22 protein and features the property of intercellular transport. We therefore generated a DNA vaccine encoding MDV-1 VP22 linked to a model antigen, human papillomavirus type 16 E7. We demonstrated that compared with mice vaccinated with DNA encoding wild-type E7, mice vaccinated with MDV-1 VP22/E7 DNA exhibited a significant increase in number of gamma-interferon-secreting, E7-specific CD8+-T-cell precursors as well as stronger tumor prevention and treatment effects. Furthermore, our data indicated that the antitumor effect was CD8 dependent. These results suggested that the development of vaccines encoding VP22 fused to a target antigen might be a promising strategy for improving DNA vaccine potency.

* Corresponding author. Mailing address: Department of Pathology, The Johns Hopkins University School of Medicine, Ross Research Building, Room 659, 720 Rutland Ave., Baltimore, MD 21205. Phone: (410) 614-3899. Fax: (410) 614-3548. E-mail: wutc{at}jhmi.edu.

Journal of Virology, March 2002, p. 2676-2682, Vol. 76, No. 6
0022-538X/02/$04.00+0     DOI: 10.1128/JVI.76.6.2676-2682.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Yao, W., Liu, S., Qu, X., Xiao, S., Liu, Y., Liu, J. (2009). Enhanced immune response and protection efficacy of a DNA vaccine constructed by linkage of the Mycobacterium tuberculosis Ag85B-encoding gene with the BVP22-encoding gene. J Med Microbiol 58: 462-468 [Abstract] [Full Text]  
  • Bae, S. H., Park, Y.-J., Park, J.-B., Choi, Y. S., Kim, M. S., Sin, J.-I. (2007). Therapeutic Synergy of Human Papillomavirus E7 Subunit Vaccines plus Cisplatin in an Animal Tumor Model: Causal Involvement of Increased Sensitivity of Cisplatin-Treated Tumors to CTL-Mediated Killing in Therapeutic Synergy. Clin. Cancer Res. 13: 341-349 [Abstract] [Full Text]  
  • Zheng, C., Babiuk, L. A., van Drunen Littel-van den Hurk, S. (2005). Bovine Herpesvirus 1 VP22 Enhances the Efficacy of a DNA Vaccine in Cattle. J. Virol. 79: 1948-1953 [Abstract] [Full Text]  
  • Garg, S., Oran, A. E., Hon, H., Jacob, J. (2004). The Hybrid Cytomegalovirus Enhancer/Chicken {beta}-Actin Promoter along with Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element Enhances the Protective Efficacy of DNA Vaccines. J. Immunol. 173: 550-558 [Abstract] [Full Text]  
  • Devaraj, K., Gillison, M. L., Wu, T.-C. (2003). DEVELOPMENT OF HPV VACCINES FOR HPV-ASSOCIATED HEAD AND NECK SQUAMOUS CELL CARCINOMA. CROBM 14: 345-362 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»